Belmore Neidrauer successfully represented Janssen in two summary trials in the Federal Court on infringement issues against Pharmascience and Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia. These decisions represent a significant advance in the application of the law relating to induced infringement.